Advances in Heart Failure - Is it Time to Redefine Patient Selection for Sodium-glucose co-transporter 2 Inhibitors?

PART 1: SGLT2s as a Heart Failure Drug – How Did We Get Here?

Learning objectives

  • Discuss current SGLT2 data and guideline recommendations for utilization in heart failure
  • Evaluate emerging data on the treatment of heart failure with SGLT2 inhibitors
  • Understand the implications of emerging data on the treatment of heart failure with SGLT2 inhibitors for clinical practice.
Martin R Cowie
National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, London

 


Programme Outline
  • PART 1: SGLT2s as a Heart Failure Drug – How Did We Get Here?Martin R Cowie
  • PART 2: Emerging Data SGLT2 Inhibitors in Heart FailureFaiez Zannad
  • PART 3: Guidelines and Practice ImplicationsSanjay Kaul
  • PART 4: Q&A DiscussionMartin R CowieFaiez ZannadSanjay Kaul
  • PART 5: Follow-up Peer-to Peer DiscussionAndrew JS CoatsFaiez Zannad
This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

PART 2: Emerging Data SGLT2 Inhibitors in Heart Failure